Clinical Trials Logo

Hepatocellular Carcinoma clinical trials

View clinical trials related to Hepatocellular Carcinoma.

Filter by:

NCT ID: NCT03739164 Enrolling by invitation - Clinical trials for Hepatocellular Carcinoma

Tampa Associating Microwave Liver Ablation With Portal Vein Ligation for Staged Hepatectomy (TAMLAPS)

TAMLAPS
Start date: July 18, 2018
Phase:
Study type: Observational [Patient Registry]

This is a study following the outcomes and survival of patients undergoing the TAMLAPS hepatectomy at Florida Hospital Tampa by Dr. Iswanto Sucandy

NCT ID: NCT03738111 Not yet recruiting - Clinical trials for Hepatocellular Carcinoma

Study of TG02 Citrate in Patients With Advanced Hepatocellular Carcinoma

Start date: December 2018
Phase: Phase 1
Study type: Interventional

This is a single-centre, open-label, dose escalation, Phase 1 study. The primary objective is to determine the highest dose of TG02 citrate that can safely be given to patients with advanced hepatocellular carcinoma.

NCT ID: NCT03734926 Not yet recruiting - Colorectal Cancer Clinical Trials

A Phase 1 Study of ZSP1241 in Participants With Advanced Solid Tumors

Start date: November 20, 2018
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics, and determine the maximum tolerated dose of ZSP1241 in participants with hepatocellular carcinoma, cholangiocarcinoma, gastric cancer, esophageal cancer, colorectal cancer and other advanced solid tumors.

NCT ID: NCT03734068 Recruiting - Clinical trials for Hepatocellular Carcinoma

Chemoembolization Using LifePearl Polyethylene Glycol Drug Eluting Microspheres With Doxorubicin in HCC

LIFDOX
Start date: June 13, 2018
Phase:
Study type: Observational

The aim of this study is to collect data on efficacy and tolerability on a large series of patient of different Italian hospitals in order to support the validation of LifePearl with robust and consistent clinical evidence. Since TACE in treating HCC is considered a more common and accepted approach, this study will be focused on evaluating treatment efficacy and safety of LIFDOX for un-resectable hepatocellular carcinoma.

NCT ID: NCT03732105 Not yet recruiting - Clinical trials for Hepatocellular Carcinoma

Radiotherapy/Apatinib for Adjuvant Treatment of HCC Patients receIved Curative reSEction With Microvascular Invasion

RAISE
Start date: November 1, 2018
Phase: Phase 2
Study type: Interventional

RAISE is a multicenter phase II randomized 2x2 factorial trial. The purpose is to further investigate both the efficacy and safety of the radiotherapy/apatinib for adjuvant treatment of HCC patients accepted radical resection with microvascular invasion.

NCT ID: NCT03731923 Recruiting - Clinical trials for Hepatocellular Carcinoma

Abbreviated MRI for HCC Surveillance

Start date: November 8, 2018
Phase: N/A
Study type: Interventional

This study aims to investigate the clinical feasibility of abbreviated liver MRI for HCC surveillance in a high-risk group.

NCT ID: NCT03731910 Not yet recruiting - Clinical trials for Hepatocellular Carcinoma

Short-term MRI for Treatment Response Evaluation/Prediction of HCC Treated With TARE

Start date: November 20, 2018
Phase: N/A
Study type: Interventional

This study aims to investigate the value of early change at MRI in HCC treated with TARE, for evaluation/prediction of treatment response and prognosis.

NCT ID: NCT03730675 Not yet recruiting - Clinical trials for Hepatocellular Carcinoma

Irradiation Stent Placement Plus TACE for HCC and PVTT

Start date: November 2018
Phase: N/A
Study type: Interventional

The study is a multicenter, randomized (1:1), open-label, parallel-arm, Phase 3 clinical trial to evaluate the efficacy and safety of portal irradiation stent placement plus TACE compared to sorafenib plus TACE in patients with advanced HCC accompanied by portal vein tumor thrombosis. Patients will be randomized to receive either portal irradiation stent placement plus TACE(Arm A) or Sorafenib plus TACE (Arm B).

NCT ID: NCT03722875 Not yet recruiting - Clinical trials for Hepatocellular Carcinoma

SHR-1210 Plus Apatinib in Patients With Hepatocellular Carcinoma After Surgery

Start date: November 1, 2018
Phase: N/A
Study type: Interventional

SHR-1210 is a humanized anti-PD1 Immunoglobulin G4 (IgG4) monoclonal antibody. This is an open- label,single center ,non-randomized ,Single Arm Exploratory Study . This clinical study is an investigator-initiatedclini-cal trial(IIT ).The objective of this study is to evaluate the efficacy and safety of adjuvant therapy with anti-PD-1 antibody SHR-1210 and apatinib in patients with Barcelona Clinic Liver Cancer (BCLC) B&C stage hepatocellular carcinoma after surgery.

NCT ID: NCT03722628 Not yet recruiting - Clinical trials for Hepatocellular Carcinoma

The Assesment of MMP-1 Genotypes Polymorphism as a Risk Factor for HCC in Chronic HCV Patients With LC

Start date: December 15, 2018
Phase:
Study type: Observational

Egypt is an endemic area of HCV.Cirrhosis and HCC are the most serious complications of chronic HCV infection.Some studies noted that the risk of HCC increased 17-fold among HCV-infected patients compared with anti-HCV negative controls. Many studies demonstrate that direct antiviral therapy seems to accelerate the development of HCC, soon after the end of treatment, in those patients at higher risk of HCC occurrence or recurrence; and preliminary reports seem to indicate that HCC developed after direct antiviral therapy has more aggressive features. These findings clearly indicate the need for aggressive and close monitoring of cirrhotic patients during and after antiviral treatment, to detect and treat HCC at their earliest occurrence. Genetic variation plays a key role in HCC susceptibility and development of the disease.Genotype distribution frequency data can be used to map single nucleotide polymorphism (SNP) diversity in a population and to examine the risk and development of specific diseases.Many reports indicate an association between SNPs in certain genes and the susceptibility and clinicopathological status of HCC. MMP-1 is an endogenous peptide enzyme that is most widely expressed in interstitial collagenase,which can degrade the extracellular matrix surrounding tumor cells. It is involved in many stages of tumorigenesis, in angiogenesis, and in suppression of tumor cell apoptosis . MMP‑1 − 1607 1G/2G (rs1799750) contains a guanine insertion/deletion polymorphism at position − 1607 and is a functional (SNP) that can upregulate MMP expression. The association between the MMP‑1 − 1607 1G/2G polymorphism and the emergence of several diseases including the risk for many cancers has been reported. There are results suggest that MMP-1 is overexpressed in a large proportion of patients with HCC which correlated with the disease progression and poor clinical outcome. Furthermore, MMP-1 high expression proved to be a risk factor for tumor recurrence and independent molecular marker of prognosis in HCC and may become a novel target in the strategies for the prediction of tumor progression and prognosis of this disease. Aim: Is to asses: The contribution of MMP‑1-1607 genotype polymorphism to the risk of HCC on top of HCV. The relationship between MMP‑1−1607 gene polymorphism with HCC in patients who received antiviral treatment to HCV.